These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11970955)

  • 1. Inhibition of platelet adhesion and aggregation by a defined region (Gly-486-Lys-502) of high molecular weight kininogen.
    Chavakis T; Boeckel N; Santoso S; Voss R; Isordia-Salas I; Pixley RA; Morgenstern E; Colman RW; Preissner KT
    J Biol Chem; 2002 Jun; 277(26):23157-64. PubMed ID: 11970955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions.
    Chavakis T; Kanse SM; Lupu F; Hammes HP; Müller-Esterl W; Pixley RA; Colman RW; Preissner KT
    Blood; 2000 Jul; 96(2):514-22. PubMed ID: 10887113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen.
    Chavakis T; Kanse SM; Pixley RA; May AE; Isordia-Salas I; Colman RW; Preissner KT
    FASEB J; 2001 Nov; 15(13):2365-76. PubMed ID: 11689462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function.
    Chavakis T; Pixley RA; Isordia-Salas I; Colman RW; Preissner KT
    J Biol Chem; 2002 Sep; 277(36):32677-82. PubMed ID: 12082110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of angiogenesis by cleaved high molecular weight kininogen (HKa) and HKa domain 5.
    McCrae KR; Doñate F; Merkulov S; Sun D; Qi X; Shaw DE
    Curr Cancer Drug Targets; 2005 Nov; 5(7):519-28. PubMed ID: 16305348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD.
    Rahman S; Lu X; Kakkar VV; Authi KS
    Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):223-32. PubMed ID: 7492316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
    Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
    Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib.
    Chavakis T; Santoso S; Clemetson KJ; Sachs UJ; Isordia-Salas I; Pixley RA; Nawroth PP; Colman RW; Preissner KT
    J Biol Chem; 2003 Nov; 278(46):45375-81. PubMed ID: 12952972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-guided design of a high-affinity platelet integrin αIIbβ3 receptor antagonist that disrupts Mg²⁺ binding to the MIDAS.
    Zhu J; Choi WS; McCoy JG; Negri A; Zhu J; Naini S; Li J; Shen M; Huang W; Bougie D; Rasmussen M; Aster R; Thomas CJ; Filizola M; Springer TA; Coller BS
    Sci Transl Med; 2012 Mar; 4(125):125ra32. PubMed ID: 22422993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitronectin binds to activated human platelets and plays a role in platelet aggregation.
    Asch E; Podack E
    J Clin Invest; 1990 May; 85(5):1372-8. PubMed ID: 1692034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrin-incorporated vitronectin is involved in platelet adhesion and thrombus formation through homotypic interactions with platelet-associated vitronectin.
    Wu YP; Bloemendal HJ; Voest EE; Logtenberg T; de Groot PG; Gebbink MF; de Boer HC
    Blood; 2004 Aug; 104(4):1034-41. PubMed ID: 15069014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to GPIIb alpha (300-312) inhibit Fg binding, clot retraction, and platelet adhesion to multiple ligands.
    Taylor DB; Derrick JM; Gartner TK
    Proc Soc Exp Biol Med; 1994 Jan; 205(1):35-43. PubMed ID: 7509487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human platelet activation is inhibited by the occupancy of glycoprotein IIb/IIIa receptor.
    Padoin E; Alexandre A; Cavallini L; Polverino de Laureto P; Rao GH; Doni MG
    Arch Biochem Biophys; 1996 Sep; 333(2):407-13. PubMed ID: 8809080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential antagonism of the interactions of the integrin alpha IIb beta 3 with immobilized glycoprotein ligands by snake-venom RGD (Arg-Gly-Asp) proteins. Evidence supporting a functional role for the amino acid residues flanking the tripeptide RGD in determining the inhibitory properties of snake-venom RGD proteins.
    Lu X; Williams JA; Deadman JJ; Salmon GP; Kakkar VV; Wilkinson JM; Baruch D; Authi KS; Rahman S
    Biochem J; 1994 Dec; 304 ( Pt 3)(Pt 3):929-36. PubMed ID: 7529494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the binding domains of the alpha(IIb) subunit. A study performed on the activated form of the platelet integrin alpha(IIb)beta(3).
    Biris N; Abatzis M; Mitsios JV; Sakarellos-Daitsiotis M; Sakarellos C; Tsoukatos D; Tselepis AD; Michalis L; Sideris D; Konidou G; Soteriadou K; Tsikaris V
    Eur J Biochem; 2003 Sep; 270(18):3760-7. PubMed ID: 12950259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of platelet activation by peptide analogs of the beta(3)-intracellular domain of platelet integrin alpha(IIb)beta(3) conjugated to the cell-penetrating peptide Tat(48-60).
    Dimitriou AA; Stathopoulos P; Mitsios JV; Sakarellos-Daitsiotis M; Goudevenos J; Tsikaris V; Tselepis AD
    Platelets; 2009 Dec; 20(8):539-47. PubMed ID: 19863457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of thrombin-induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol-protease inhibitory sequence of kininogens and S-(3-nitro-2-pyridinesulfenyl)-cysteine.
    Puri RN; Matsueda R; Umeyama H; Bradford HN; Colman RW
    Eur J Biochem; 1993 May; 214(1):233-41. PubMed ID: 8389701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cleaved high-molecular-weight kininogen inhibits neointima formation following vascular injury.
    Daniel JM; Reich F; Dutzmann J; Weisheit S; Teske R; Gündüz D; Bauersachs J; Preissner KT; Sedding DG
    Thromb Haemost; 2015 Aug; 114(3):603-13. PubMed ID: 26063414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia impairs agonist-induced integrin α
    Kiouptsi K; Gambaryan S; Walter E; Walter U; Jurk K; Reinhardt C
    Sci Rep; 2017 Aug; 7(1):7621. PubMed ID: 28790378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.